|
Sciele Pharma and Plethora Solutions Announce Final Analysis of …
UroToday, CA - 2 hours ago There are currently no approved pharmaceutical treatments for premature ejaculation. In May 2007, Plethora signed an exclusive license agreement with Sciele … |
|
Sciele Pharma and Plethora Solutions Announce Final Analysis of …
UroToday, CA - 4 hours ago There are currently no approved pharmaceutical treatments for premature ejaculation. In May 2007, Plethora signed an exclusive license agreement with Sciele … |
|
Sciele Pharma and Plethora Solutions Announce Final Analysis of …
UroToday, CA - 6 hours ago There are currently no approved pharmaceutical treatments for premature ejaculation. In May 2007, Plethora signed an exclusive license agreement with Sciele … |
|
Sciele Pharma and Plethora Solutions Announce Final Analysis of …
UroToday, CA - 8 hours ago There are currently no approved pharmaceutical treatments for premature ejaculation. In May 2007, Plethora signed an exclusive license agreement with Sciele … |
|
Sciele Pharma and Plethora Solutions Announce Final Analysis of …
UroToday, CA - 10 hours ago There are currently no approved pharmaceutical treatments for premature ejaculation. In May 2007, Plethora signed an exclusive license agreement with Sciele … |
|
Sciele Pharma and Plethora Solutions Announce Final Analysis of …
MarketWatch - Dec 8, 2008 There are currently no approved pharmaceutical treatments for premature ejaculation. In May 2007, Plethora signed an exclusive license agreement with Sciele … |
 Business Wire (press release) |
Sciele Pharma and Plethora Solutions Announce Positive Phase III …
Business Wire (press release), CA - Nov 7, 2008 There are currently no approved pharmaceutical treatments for premature ejaculation. PSD502 is applied locally "on demand" and is effective within five … Plethora: Plethora reports positive outcomes of European Phase III … Proactive Investors UK all 14 news articles |